GSK falls 12% on worries over Zantac litigation

Shares of GlaxoSmithKline (GSK) fell as much as 12% Thursday on growing concern over litigation concerning the heartburn drug Zantac, the most significant drop since 1998. Along with GSK, shares of dr…